GlaxoSmithKline ranks No. 143 on FORTUNE's 2006 Global 500
(Fortune) -- GlaxoSmithKline (Charts) ranks no. 143 on FORTUNE's Global 500 this year, with $39.4 billion in revenues, up 5.5% from the previous year. The Brentford, Britain-based company was ranked no. 122 on the 2005 list. Its 2005 profits were $8.8 billion, up 8.1% from a year earlier. 2005 was a banner year for most Global 500 companies. It took $13.7 billion in revenue just to make this year's list - up from $12.4 billion last year. And profits for the 500 companies jumped 30%. Total revenues for the Global 500 in 2006 add up to $18.9 trillion, a third of the world's GDP. I n the Pharmaceuticals industry, profits were up 8.1% from the previous year. The world's biggest companies in the sector are: Pfizer (Charts), ranked no. 101 on the Global 500 with $51.4 billion in revenues; Johnson & Johnson (Charts), ranked no. 104 on the Global 500 with $50.5 billion in revenues; Sanofi-Aventis (Charts), ranked no. 159 on the Global 500 with $35.4 billion in revenues; and Novartis Group (Charts), ranked no. 177 on the Global 500 with $32.2 billion in revenues. The Global 500 list is an annual ranking of the world's largest corporations by revenues. Next: Full list: 2006 Global 500 at //money.cnn.com/global500 Plus: See GlaxoSmithKline's Global 500 details, including financial stats and contact information. Next: See 2006 FORTUNE Global 500Europe's top 50 Asia's top 50 |
|